Print

HVTN 064

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants

Trial Details:

I Completed
Pharmexa-Epimmune, National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN) January 13, 2006
EP HIV-1043 ,EP HIV-1090 Protein Pol, vpu, gag; DNA gag,pol, env, neft, rev, vpr
EP HIV-1043 Protein
EP HIV-1090 Protein
USA 120
NCT00141024
http://www.clinicaltrials.gov/ct/show/NCT00141024?order=1